Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes

Cancer Discovery

Volumn 4, Issue 12, 2014, Pages 1398-1405

  Chmielecki, Juliann ^a   Hutchinson, Katherine E ^b   Frampton, Garrett M ^a   Chalmers, Zachary R ^a   Johnson, Adrienne ^a   Shi, Chanjuan ^b   Elvin, Julia ^a   Ali, Siraj M ^a   Ross, Jeffrey S ^a,c   Basturk, Olca ^d   Balasubramanian, Sohail ^a   Lipson, Doron ^a   Yelensky, Roman ^a   Pao, William ^b   Miller, Vincent A ^a   Klimstra, David S ^d   Stephens, Philip J ^a  

^a FOUNDATION MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BETA CATENIN; BRCA2 PROTEIN; COMPLEMENTARY DNA; HYBRID PROTEIN; K RAS PROTEIN; METHIONINE; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEAR FACTOR I; ORAL ANTIDIABETIC AGENT; RAF PROTEIN; SORAFENIB; TAK 632; TRAMETINIB; UNCLASSIFIED DRUG; ONCOPROTEIN;

ACINAR CELL CARCINOMA; ANIMAL CELL; ARTICLE; CELL VIABILITY ASSAY; DNA EXTRACTION; DNA REPAIR GENE; GENE; GENE EXPRESSION PROFILING; GENE INACTIVATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOUSE; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; VIRAL GENE DELIVERY SYSTEM; BIOLOGY; CELL LINE; CLUSTER ANALYSIS; DNA REPAIR; GENE SILENCING; GENE TRANSLOCATION; GENETICS; GENOMICS; METABOLISM; PANCREAS TUMOR;

CARCINOMA, ACINAR CELL; CELL LINE; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; DNA REPAIR; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION PROFILING; GENE SILENCING; GENOMICS; HUMANS; ONCOGENE PROTEINS, FUSION; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; TRANSLOCATION, GENETIC;

EID: 84915770151     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-14-0617     Document Type: Article

References (24)

1. Wisnoski NC, Townsend CM Jr, Nealon WH, Freeman JL, Riall TS. 672 patients with acinar cell carcinoma of the pancreas: a population- based comparison to pancreatic adenocarcinoma. Surgery 2008; 144: 141 - 8.
2. Abraham SC, Wu TT, Hruban RH, Lee JH, Yeo CJ, Conlon K, et al. Genetic and immunohistochemical analysis of pancreatic acinar cell carcinoma: frequent allelic loss on chromosome 11p and alterations in the APC/beta-catenin pathway. Am J Pathol 2002; 160: 953 - 62.
3. Klimstra DS, Hruban RH, Kloppel G, Morohoshi T, Ohike N. Acinar cell neoplasms of the pancreas. In: Bosman FT, Hruban RH, Carneiro F, Theise ND, editors. WHO classification of tumours of the digestive system. 4th ed. Lyon, France: IARC; 2010. p. 314 - 18.
4. Holen KD, Klimstra DS, Hummer A, Gonen M, Conlon K, Brennan M, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 2002; 20: 4673 - 8.
5. Arteaga CL, Baselga J. Impact of genomics on personalized cancer medicine. Clin Cancer Res 2012; 18: 612 - 8.
6. Ohori NP, Khalid A, Etemad B, Finkelstein SD. Multiple loss of heterozygosity without K-ras mutation identified by molecular analysis on fine-needle aspiration cytology specimen of acinar cell carcinoma of pancreas. Diagn Cytopathol 2002; 27: 42 - 6.
7. Taruscio D, Paradisi S, Zamboni G, Rigaud G, Falconi M, Scarpa A. Pancreatic acinar carcinoma shows a distinct pattern of chromosomal imbalances by comparative genomic hybridization. Genes Chromosomes Cancer 2000; 28: 294 - 9.
8. Jiao Y, Yonescu R, Offerhaus GJ, Klimstra DS, Maitra A, Eshleman JR, et al. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 2014; 232: 428 - 35.
9. Frampton GM, Fichtenholtz A, Otto GA, Wang K, Downing SR, He J, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013; 31: 1023 - 31.
10. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008; 68: 8673 - 7.
11. Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010; 16: 793 - 8.
12. Hutchinson KE, Lipson D, Stephens PJ, Otto G, Lehmann BD, Lyle PL, et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. Clin Cancer Res 2013; 19: 6696 - 702.
13. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013; 13: 772 - 87.
14. Lee NV, Lira ME, Pavlicek A, Ye J, Buckman D, Bagrodia S, et al. A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation. PLoS ONE 2012; 7: e39653.
15. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199 - 203.
16. Ottenhof NA, de Wilde RF, Maitra A, Hruban RH, Offerhaus GJ. Molecular characteristics of pancreatic ductal adenocarcinoma. Pathol Res Int 2011; 2011: 620601.
17. Chen M, Van Ness M, Guo Y, Gregg J. Molecular pathology of pancreatic neuroendocrine tumors. J Gastrointest Oncol 2012; 3: 182 - 8.
18. Furukawa T, Kuboki Y, Tanji E, Yoshida S, Hatori T, Yamamoto M, et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Sci Rep 2011; 1: 161.
19. Gaujoux S, Tissier F, Ragazzon B, Rebours V, Saloustros E, Perlemoine K, et al. Pancreatic ductal and acinar cell neoplasms in Carney complex: a possible new association. J Clin Endocrinol Metab 2011; 96: E1888 - 95.
20. Greer JB, Whitcomb DC. Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut 2007; 56: 601 - 5.
21. Passeron T, Lacour JP, Allegra M, Segalen C, Deville A, Thyss A, et al. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy? Exp Dermatol 2011; 20: 1030- 2.
22. Subbiah V, Westin SN, Wang K, Araujo D, Wang WL, Miller VA, et al. Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549- BRAF fusion protein. J Hematol Oncol 2014; 7: 8.
23. Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 2011; 105: 1114 - 22.
24. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011; 39: D945 - 50.